Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease | MicrobiomeTrials← Back to trialsNCT06984484
Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2025-07-02Est. Completion: 2027-01
Enrollment target: 208 participants Locations- IRCCS Policlinico San Martino, Genova, Italy
- IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milan, Italy
- AOU Federico II di Napoli, Naples, Italy
- Azienda Ospedale Università Padova, Padova, Italy
- S. Andrea Ospedale Universitario, Roma, Italy
- Humanitas Research Hospital, Rozzano (MI), Italy
- A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
Other microbiome trials you might be interested in
Hepatic Encephalopathy
A total of 40 patients taking proton pump inhibitors (PPIs) who undergo transjugular intrahepatic portosystemic shunt (T…
Durham, United StatesCompleted Jun 2, 2025
Esophageal AchalasiaEsophageal Motility DisordersGastroesophageal Reflux
Achalasia is a disorder of the esophagus in which the muscular valve between the esophagus and the stomach fails to rela…
Minya, EgyptEst. completion Sep 20, 2028
GERD
GERD is a chronic disease the require different treatment modalities; non have proven long term efficacy with concerns a…
Cairo, EgyptEst. completion Jan 1, 2028